Stay informed about our latest news and updates! Sign up for email alerts here: https://bit.ly/3zXgBLd #Oncology #SolidTumors #PancreaticCancer #CARTcells #DNase
Xenetic Biosciences, Inc.
Biotechnology Research
Framingham, MA 740 followers
Enhancing Lives with Transformative Therapies
About us
Xenetic Biosciences, Inc. (NASDAQ: XBIO) is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications. Additionally, Xenetic is leveraging PolyXen™, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. PolyXen™ has demonstrated its ability to improve the half-life and other pharmacological properties of next-generation biologic drugs. The Company has an exclusive license agreement with Takeda Pharmaceuticals Co. Ltd. in the field of coagulation disorders and expects to earn royalty payments under this agreement.
- Website
-
http://www.xeneticbio.com/
External link for Xenetic Biosciences, Inc.
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Headquarters
- Framingham, MA
- Type
- Public Company
Locations
-
Primary
Get directions
40 Speen Street
Suite 102
Framingham, MA 01701, US
Employees at Xenetic Biosciences, Inc.
Updates
-
Learn more about NETs role in cancer and how our DNase I Oncology Platform is designed to work here: https://bit.ly/43jxnTE #NationalCancerControlMonth #Oncology #SolidTumors #PancreaticCancer #CARTcells #DNase
-
#DidYouKnow #PancreaticCarcinoma is the 3rd deadliest cancer in the world? Learn how Xenetic is working to address this unmet need: https://bit.ly/4cltVw0 #NationalCancerControlMonth #Oncology #SolidTumors #PancreaticCancer #CARTcells #DNase
-
-
Xenetic is focused on advancing proprietary technology platforms across multiple high-value cancer indications. #NationalCancerControlMonth #Oncology #SolidTumors #PancreaticCancer #CARTcells #DNase
-
-
April is #NationalCancerControlMonth. The focus is improving cancer treatments and increasing the survival rate of cancer. Want to make a difference? Learn more here: https://bit.ly/4cbes1D #Oncology #SolidTumors #PancreaticCancer #CARTcells #DNase
-
-
Stay informed about our latest news and updates! Sign up for email alerts here: https://bit.ly/3zXgBLd #Oncology #SolidTumors #PancreaticCancer #CARTcells #DNase
Email Alerts :: Xenetic Biosciences, Inc. (XBIO)
ir.xeneticbio.com
-
Xenetic Biosciences, Inc. Reports Full Year 2023 Financial Results https://bit.ly/43qIpGV #Oncology #SolidTumors
Xenetic Biosciences, Inc. Reports Full Year 2023 Financial Results :: Xenetic Biosciences, Inc. (XBIO)
xeneticbio.com
-
NETs in Cancer: NETs are a driver of cancer progression and metastasis and can also contribute to resistance to chemotherapy, checkpoint inhibitors and radiotherapy. https://bit.ly/3xixJIx #Oncology #SolidTumors
Xenetic Biosciences, Inc. (XBIO)
xeneticbio.com
-
Our oncology platform is aimed at improving cancer therapies with the opportunity to address multiple oncology indications, including pancreatic cancer and other solid tumors. https://bit.ly/47BUWHN #Oncology #SolidTumors #PancreaticCancer #CARTcells #DNase
-
-
Take a look at our innovative oncology pipeline here: https://bit.ly/47BUWHN #Oncology #SolidTumors #PancreaticCancer #CARTcells #DNase
-